Latest news with #TylerVanBuren
Business Insider
15-05-2025
- Business
- Business Insider
TD Cowen Remains a Buy on Oruka Therapeutics (ORKA)
In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Oruka Therapeutics (ORKA – Research Report). The company's shares closed today at $9.71. Confident Investing Starts Here: Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter According to TipRanks, Van Buren is an analyst with an average return of -5.2% and a 36.16% success rate. Van Buren covers the Healthcare sector, focusing on stocks such as BridgeBio Pharma, Regeneron, and Travere Therapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Oruka Therapeutics with a $44.75 average price target. The company has a one-year high of $53.88 and a one-year low of $5.49. Currently, Oruka Therapeutics has an average volume of 261.7K. Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ORKA in relation to earlier this year. Most recently, in February 2025, Venrock Healthcare Capital Partners III, L.P., a Major Shareholder at ORKA bought 122,882.00 shares for a total of $1,407,367.87.
Business Insider
15-05-2025
- Business
- Business Insider
Maze Therapeutics, Inc. (MAZE) Gets a Buy from TD Cowen
In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Maze Therapeutics, Inc. (MAZE – Research Report). The company's shares closed today at $9.06. Confident Investing Starts Here: Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter According to TipRanks, Van Buren is an analyst with an average return of -5.2% and a 36.16% success rate. Van Buren covers the Healthcare sector, focusing on stocks such as BridgeBio Pharma, Regeneron, and Travere Therapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Maze Therapeutics, Inc. with a $25.67 average price target.
Business Insider
14-05-2025
- Business
- Business Insider
Allogene Therapeutics (ALLO) Receives a Buy from TD Cowen
In a report released yesterday, Tyler Van Buren from TD Cowen maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report). The company's shares closed yesterday at $1.13. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Van Buren covers the Healthcare sector, focusing on stocks such as BridgeBio Pharma, Regeneron, and Travere Therapeutics. According to TipRanks, Van Buren has an average return of -4.6% and a 38.02% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Allogene Therapeutics with a $8.50 average price target. Based on Allogene Therapeutics' latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $59.94 million. In comparison, last year the company earned a revenue of $21 thousand and had a GAAP net loss of $85.78 million
Business Insider
13-05-2025
- Business
- Business Insider
Immunome (IMNM) Receives a Buy from TD Cowen
TD Cowen analyst Tyler Van Buren reiterated a Buy rating on Immunome (IMNM – Research Report) today. The company's shares closed today at $7.94. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Van Buren covers the Healthcare sector, focusing on stocks such as BridgeBio Pharma, Regeneron, and Moderna. According to TipRanks, Van Buren has an average return of -6.3% and a 35.20% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Immunome with a $27.00 average price target. IMNM market cap is currently $649.1M and has a P/E ratio of -1.44. Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of IMNM in relation to earlier this year. Most recently, in March 2025, Jean Jacques Bienaime, a Director at IMNM bought 7,800.00 shares for a total of $60,684.00.
Yahoo
24-02-2025
- Business
- Yahoo
BridgeBio price target raised to $52 from $49 at Scotiabank
Scotiabank raised the firm's price target on BridgeBio (BBIO) to $52 from $49 and keeps an Outperform rating on the shares. The company's earnings release reflects 'stellar commercial momentum' in the early launch of Attruby in transthyretin amyloid cardiomyopathy, the analyst tells investors. In the firm's view, the rapid uptake of Attruby is reflective of the robust and broad incentive to prescribe the drug as a first line of defense given its clinical profile. See what stocks are receiving strong buy ratings from top-rated analysts. Filter, analyze, and streamline your search for investment opportunities with TipRanks' Stock Screener. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on BBIO: BridgeBio price target raised to $67 from $58 at Wells Fargo BridgeBio price target raised to $49 from $45 at Citi Positive Outlook for BridgeBio Pharma Due to Accelerating Patient Growth and Promising Drug Pipeline BridgeBio Pharma Reports Strong 2024 Financial Results BridgeBio Pharma's Growth Potential and Strategic Positioning: A Buy Recommendation by Tyler Van Buren Sign in to access your portfolio
